OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, Sept. 3, 2019 — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an […]